News for Aytu Biopharma, Inc. (AYTU)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / J

Aytu Biopharma, Inc. (AYTU) has expanded its previously announced stock offering from 6.7 million shares to 9.6 million shares of common stock. This decision ma

Aytu BioPharma (AYTU) has entered into an exclusive agreement to bring Exxua, an extended-release tablet containing gepirone, to the U.S. market. Approved by th

Operator: Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call. At this time, all participants are in a listen-only.

Net Revenue: $18.5 million, surpassing the estimated $13.74 million, marking a 32% increase year-over-year.Net Income: Achieved $4.0 million, or $0.65 and $0.2

Release Date: May 14, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aytu BioPharma In

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAYTU.OQ - Aytu Biopharma IncQ3 2025 Aytu Biopharma Inc Earnings CallMay 14, 2025 / 08:30PM GMT

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 mi

On February 28, 2025, Joshua Disbrow, the Chief Executive Officer of Aytu BioPharma Inc, purchased 15,000 shares of the company, as reported in a SEC Filing. Fo

**media[548579]**

Release Date: February 12, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aytu BioPhar

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAYTU.OQ - Aytu Biopharma IncQ2 2025 Aytu Biopharma Inc Earnings CallFeb 12, 2025 / 09:30PM GMT

Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase fo

Earnings Call Insights: Aytu BioPharma (NASDAQ:AYTU) Q2 2025Management ViewCEO Josh Disbrow reported that both the ADHD and pediatric portfolios achieved...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ETCompany ParticipantsRobert Blum - Investor Relations, Lytham...

Ironwood Pharmaceuticals (IRWD) recently experienced a significant stock price drop of 5.20%, bringing its share price to $3.58. The trading volume reached 431,

DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing no

SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ( ACHV), a late-stage pharmaceutical company dedicated